Kura Oncology (KURA) – Research Analysts’ Weekly Ratings Changes

Kura Oncology (NASDAQ: KURA) recently received a number of ratings updates from brokerages and research firms:

• 10/14/2026 – Kura Oncology was given a new $24.00 price target by Barclays PLC.
• 10/14/2026 – Kura Oncology was given a new $24.00 price target by Deutsche Bank Aktiengesellschaft.
• 10/14/2026 – Kura Oncology had its “market outperform” rating reaffirmed by Citigroup Inc..
• 10/5/2026 – Kura Oncology had its “buy” rating reaffirmed by UBS Group AG.
• 10/1/2026 – Kura Oncology is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $30.00 price target on the stock.
• 8/24/2026 – Kura Oncology was given a new $24.00 price target by Raymond James Financial, Inc..
• 8/24/2026 – Kura Oncology was given a new $24.00 price target by Morgan Stanley.
• 8/24/2026 – Kura Oncology had its “market outperform” rating reaffirmed by Citigroup Inc..
• 8/24/2026 – Kura Oncology had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $24.00 price target on the stock.

Insider Buying and Selling

In related news, insider Mollie Leoni sold 28,802 shares of the business’s stock in a transaction that occurred on Tuesday, September 29th. The shares were sold at an average price of $10.75, for a total transaction of $309,621.50. Following the completion of the transaction, the insider owned 141,095 shares of the company’s stock, valued at approximately $1,516,771.25. The trade was a 16.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Teresa Bair sold 31,487 shares of the business’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $12.63, for a total transaction of $397,680.81. Following the transaction, the insider owned 195,444 shares of the company’s stock, valued at $2,468,457.72. This trade represents a 13.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 153,881 shares of company stock valued at $1,708,183 in the last three months. Insiders own 7.60% of the company’s stock.

Kura Oncology, Inc is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company uses molecular and genomic insights to identify therapies designed to target specific biological drivers of tumor growth.

Kura’s lead program is ziftomenib, an oral menin inhibitor developed for genetically defined forms of acute myeloid leukemia, including disease associated with NPM1 mutations and KMT2A rearrangements. The company has also evaluated additional targeted oncology candidates, including therapies directed at the RAF-MEK-ERK signaling pathway.

Founded in 2014 and headquartered in San Diego, California, Kura has conducted clinical development activities through research collaborations and studies involving patients and institutions in the United States and other regions.